This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Galactokinase Deficiency / GALK1 Deficiency / Type II Galactosemia갈락토카이네이스결핍

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.2 (galactosemia) | Special Copayment Reduction: V117 (ultra-rare disease)
B. SynonymsGalactokinase deficiency, Galactosemia type II, GALK1 deficiency, Galactokinase-1 deficiency, Galactokinase-1 (GALK1) deficiency, Galactosemia due to galactokinase deficiency, Neonatal cataracts due to galactokinase deficiency
C. Adult onsetPossible first onset in adulthood: yes — in patients with mild or partial deficiency, cataracts may go undetected in infancy and progress through childhood, adolescence and adulthood until first discovered due to decreased vision. Because there are no systemic complications besides cataracts, it is sometimes diagnosed incidentally in adulthood.
1. History1969: Gitzelmann first described infantile cataracts due to galactokinase deficiency. 2000: GALK1 gene mapped and variants identified.
2. CausesPathogenic variants in the GALK1 gene (17q24.2) → galactokinase-1 deficiency → blocked galactose phosphorylation → accumulation of galactose and galactitol → lens cataract.
3. GeneticsAutosomal recessive. GALK1 gene at 17q24.2. Founder variant (p.Pro28Thr) at high frequency in the Romani (Roma) population. About 40 variants reported to date.
4. General epidemiologyPrevalence about 1/100,000 births. Markedly higher in the European Romani (Roma) population at 1/4,000–1/15,000. Occurs in all ethnic groups worldwide.
5. PathophysiologyGALK1 deficiency → blocked conversion of galactose → galactose-1-phosphate → galactose accumulation in blood → conversion to galactitol by aldose reductase → osmotic accumulation within the lens → lens fiber damage → cataract.
6. SymptomsEarly infantile cataract (oil-drop nuclear cataract) is almost the only clinical symptom. Systemic symptoms (hepatomegaly, liver failure, sepsis, cognitive impairment) do not occur. Decreased vision, strabismus and nystagmus are early clues to detection.
7. SignsPosterior subcapsular or nuclear cataract on slit-lamp examination. Leukocoria, elevated urinary galactose and galactitol, elevated blood galactose. Normal GALT activity (distinguishing point from classical galactosemia).
8. ScreeningNewborn screening in some countries (detectable by total galactose measurement methods). Korea: when blood galactose is elevated on the newborn screening galactose panel, differential diagnosis includes GALK1. Bilateral infantile cataracts are the key clinical clue to GALK1 deficiency.
9. DiagnosisMeasurement of erythrocyte GALK1 enzyme activity (< 5% of normal = confirmed). Molecular genetic testing of the GALK1 gene. Measurement of blood galactose and urinary galactitol. Confirmation of normal GALT activity (to exclude classical galactosemia).
10. TreatmentGalactose- and lactose-restricted diet (immediately upon diagnosis). If treated before cataract formation, surgery is unnecessary. Existing cataract: surgical removal (lens extraction) + visual correction (intraocular lens or eyeglasses). Early intervention is decisive for visual prognosis.
11. PrognosisPrognosis very good with early diagnosis and dietary treatment. No systemic complications. If cataracts have already formed, visual correction after surgery. Late diagnosis or delayed treatment carries a risk of irreversible visual loss or amblyopia. Normal life expectancy.
12. PreventionEarly diagnosis by newborn screening. Genetic counseling and prenatal testing. Prevention of cataract formation with a galactose-restricted diet in infancy. GALK1 deficiency must be included in the differential diagnosis when evaluating infantile cataracts.
13. ReferencesGitzelmann R (1967, 1969) and 9 other references.

1. History

The history of galactokinase deficiency (GALK1 deficiency, galactosemia type II) begins with the research of Swiss pediatric biochemist Richard Gitzelmann in the 1960s. In 1967 and 1969, Gitzelmann discovered a deficiency of the enzyme galactokinase (GALK) in children who showed galactosuria similar to galactosemia (classical type, GALT deficiency) but had normal GALT enzyme activity. He described cataracts arising in infancy as the only clinical symptom in these patients, and proposed that blocking galactose accumulation and galactitol formation with a galactose-restricted diet could prevent cataract formation.

Gitzelmann's discovery helped make clear that disorders of galactose metabolism are not a single disease but consist of several subtypes caused by different enzyme deficiencies. Whereas classical galactosemia (GALT deficiency, Type I) is a systemic disease involving multiple organs, GALK1 deficiency (Type II) was recognized as a simpler form of galactose metabolism disorder that almost exclusively involves the lens and causes only cataracts.

In 1973, a method for measuring enzyme activity in erythrocytes of GALK-deficient patients was established, facilitating biochemical diagnosis. However, molecular identification of the GALK1 gene was long delayed; in the early 2000s, the GALK1 gene was confirmed to be located on chromosome 17 (17q24.2) and pathogenic variants began to be identified. In particular, the p.Pro28Thr variant due to a founder effect was found at high frequency in the European Romani (Roma) population, and prevalence in this population was reported to be markedly higher than in the general population.

GALK1 deficiency is now recognized as the most easily preventable form of galactosemia, and it is established that early diagnosis through newborn screening and initiation of a galactose-restricted diet can completely prevent cataract formation. The clinical importance of this disease as 'a cause of treatable infantile cataract' is emphasized. In Korea, galactose measurement is included in the newborn metabolic screening panel, enabling early detection of GALK1 deficiency, but cases of delayed diagnosis due to lack of awareness are still reported.


2. Causes

Galactokinase deficiency (GALK1 deficiency) is an autosomal recessive genetic disorder caused by deficient or markedly reduced galactokinase-1 (GALK1) enzyme activity due to pathogenic variants in the GALK1 gene (galactokinase 1; 17q24.2). GALK1 is the enzyme that catalyzes the first reaction of the Leloir pathway of galactose metabolism, using ATP and galactose as substrates to produce galactose-1-phosphate (Gal-1-P) and ADP. When this reaction is blocked, galactose cannot be converted to Gal-1-P and accumulates in the blood.

The accumulated galactose is converted by aldose reductase to the sugar alcohol galactitol. Galactitol is a non-metabolizable end product that is not readily released from cells and therefore accumulates intracellularly. In the lens in particular, this osmotic accumulation draws in surrounding water, destroying lens fibers and causing denaturation and aggregation of lens proteins (especially crystallins), forming a cataract.

The reason GALK1 deficiency differs fundamentally from classical galactosemia (GALT deficiency, Type I) is that when GALT is deficient, Gal-1-P accumulates to toxic levels and damages systemic organs such as the liver, kidneys and brain, whereas when GALK1 is deficient, Gal-1-P itself is not formed and there is no systemic toxicity. In GALK1 deficiency, galactitol accumulation is the main pathophysiology, and galactitol is relatively nontoxic in tissues other than the lens even at high blood concentrations. For this reason, GALK1 deficiency shows a simple clinical phenotype in which cataract is the only clinical manifestation, without systemic symptoms.

About 40 pathogenic variants in the GALK1 gene have been reported to date. The best-known founder variant is p.Pro28Thr (c.82C>A), found at high frequency in the European Romani (Roma) population, which is why the prevalence of GALK1 deficiency in this population is several times higher than in the general population. Other variants such as p.Arg256Trp, p.Ala198Val and p.Gly346Ser have been reported in various ethnic groups.


3. Genetics

GALK1 deficiency is inherited in an autosomal recessive manner. The GALK1 gene is located on the long arm of chromosome 17 (17q24.2) and consists of 8 exons. The GALK1 protein is a homodimer composed of 394 amino acids and contains an ATP-binding domain and a galactose-binding site. Its catalytic mechanism is a bisubstrate mechanism, carrying out a phosphotransferase reaction that transfers a phosphate group from ATP to galactose.

Genotype–phenotype correlation: Most GALK1 variants reduce enzyme activity to less than 5% of normal, conferring a high risk of infantile cataract. In patients with mild variants that preserve residual enzyme activity at 5–20%, cataract onset may be later or milder. Heterozygous carriers have about 50% enzyme activity and no clinical symptoms, but some reports suggest an increased risk of mild cataract in adulthood even in heterozygotes, which remains debated.

With the p.Pro28Thr founder variant in the Romani (Roma) population, the carrier frequency in this population reaches about 1/40–1/60, greatly increasing the prevalence of galactokinase deficiency. Screening programs targeting this population are conducted in some countries. In Asian patients, including Korean patients, the Romani-specific variant is rare and various sporadic variants have been reported.

Genetic counseling: When both parents are GALK1 heterozygous carriers, 25% of children may be affected. For siblings of an infant with confirmed GALK1 deficiency, erythrocyte GALK1 enzyme activity measurement and molecular genetic testing are performed immediately so that a galactose-restricted diet can be started early. Preimplantation genetic testing (PGT-M) and prenatal genetic testing (chorionic villus sampling, amniocentesis) are presented as options.


4. General epidemiology

The worldwide prevalence of galactokinase deficiency (GALK1 deficiency) is estimated at about 1/100,000 births. This is rarer than classical galactosemia (about 1/30,000–60,000) and is a relatively rare form even among the galactosemias. However, if undiagnosed mild cases are included, the actual prevalence is estimated to be higher.

In terms of sex distribution, it occurs equally in males and females in accordance with autosomal recessive inheritance. The most prominent ethnic feature is the markedly high prevalence in the European Romani (Roma) population, where, owing to the p.Pro28Thr founder variant, it is about 1/4,000–1/15,000, several to tens of times higher than in the general population. There are reports that a substantial proportion of infants with cataracts due to galactokinase deficiency at medical institutions in Eastern Europe and the Balkan Peninsula are of Romani origin.

The epidemiological situation in Korea is known only to a very limited extent. It can be detected through elevated blood galactose on newborn metabolic screening, but must be distinguished from positive results for GALT deficiency (classical galactosemia). In Korea, GALK1 deficiency is often diagnosed by metabolic testing after infantile cataract is first detected in pediatric ophthalmology. The exact number of registered patients in Korea is difficult to determine from public data. It is included in the Korea Disease Control and Prevention Agency (KDCA) list of ultra-rare diseases (V117).


5. Pathophysiology

The pathophysiology of galactokinase deficiency stems from a block of the first enzyme of the Leloir pathway of galactose metabolism. Normally, dietary galactose (a breakdown product of lactose) is absorbed in the small intestine, transported to the liver and converted to glucose-1-phosphate via the Leloir pathway. GALK1 is responsible for the first step of this pathway, transferring a phosphate group from ATP to galactose to form galactose-1-phosphate (Gal-1-P).

When GALK1 is deficient, this phosphorylation reaction is blocked, galactose cannot be converted to Gal-1-P, and galactose accumulates in the blood. Through the systemic circulation, blood galactose is converted to galactitol in tissues expressing aldose reductase (AR), such as the lens and kidney. Aldose reductase is the key enzyme of the polyol pathway; normally it catalyzes the conversion of glucose to sorbitol, but it also has high affinity for galactose.

Mechanism of lens cataract formation: The lens is an avascular tissue without blood vessels and receives its nutrient supply through the aqueous humor. Aldose reductase present in the lens converts galactose to galactitol. Galactitol is highly hydrophilic and cannot be expelled from the lens, raising osmolality and drawing in surrounding water. As a result, lens fibers swell and rupture, and the three-dimensional structure of lens proteins (crystallin) is denatured, forming insoluble aggregates. Initially, oil-drop-shaped opacities (oil drop opacity) appear in the nucleus, and with progression, this develops into a total nuclear cataract.

Because Gal-1-P is not formed in GALK1 deficiency, the hepatotoxicity, nephrotoxicity, brain damage and increased susceptibility to sepsis seen in classical galactosemia (GALT deficiency) do not occur. This is why the clinical phenotype of GALK1 deficiency is limited to cataracts. However, the long-term effects of chronic elevation of blood galactose on other tissues are still incompletely understood, and some reports have suggested an association with neurological abnormalities.

In utero cataract formation: When the mother (carrier or affected) consumes dairy products during pregnancy, galactose is transferred to the fetus across the placenta. In an affected fetus, galactitol accumulates due to GALK1 deficiency, and lens damage may already begin in utero. This is why cataracts are detected immediately after birth or within the first few weeks of life, and it suggests that a maternal galactose-restricted diet during pregnancy may help protect the fetal lens.


6. Symptoms

The clinical symptoms of galactokinase deficiency (GALK1 deficiency) are almost exclusively limited to lens cataract. This is a decisively different clinical feature from classical galactosemia (GALT deficiency), which is the same type of galactose metabolism disorder.

Lens cataract: Early infantile cataract is the most characteristic clinical symptom. Lens opacity forms as early as a few weeks after galactose exposure (breast milk or lactose-containing formula) begins. Initially, a nuclear oil drop opacity is characteristic, observed on slit lamp examination as a nuclear opacity that looks golden or like an oil drop. With progression, it develops into total nuclear cataract and posterior subcapsular cataract. Most cases are bilateral, and one side may be more severe.

Vision-related symptoms: Initially the cataract may be mild and asymptomatic, but with progression the following findings are observed. (1) Leukocoria: a finding in which the pupil appears white, sometimes noticed by caregivers with the naked eye. (2) Decreased vision: detected by behavioral changes such as the infant being unable to follow objects or make eye contact. (3) Strabismus: when the cataract in one eye is more advanced, amblyopia and strabismus accompany it. (4) Nystagmus: occurs as a result of visual deprivation due to severe or bilateral cataracts.

Absence of systemic symptoms: Unlike classical galactosemia, hepatomegaly, liver failure, jaundice, hypoglycemia, E. coli sepsis, cognitive impairment and growth retardation do not occur. This is the key clinical distinguishing point between the two diseases. Renal function is also normal, and routine blood test results are mostly normal.

Cases detected in adulthood: When diagnosis is delayed because newborn screening or infantile eye examination was not performed, patients may first be referred in childhood, adolescence or adulthood for slowly progressive decreased vision, and cataracts may be found on eye examination. When diagnosed in adulthood, the cataract has often already progressed and surgery is frequently required.


7. Signs

Ophthalmologic findings: On slit lamp examination, nuclear oil drop opacity is an early finding characteristic of galactokinase deficiency. With progression, it develops into total nuclear cataract and posterior subcapsular opacity. Bilateral or asymmetric bilateral cataracts are observed. Fundus examination is normal when the cataract is not severe, but amblyopia and nystagmus may accompany visual deprivation due to the cataract. Opacity is observed on red reflex testing after pupil dilation.

Laboratory findings: Elevated blood galactose (total galactose) is observed. Elevated urinary galactose and galactitol are characteristic. Blood galactose-1-phosphate (Gal-1-P) is normal or mildly elevated (much lower than in classical galactosemia because GALK1 is deficient and Gal-1-P is not formed). Erythrocyte GALT enzyme activity is normal (the key distinguishing point from classical galactosemia). Erythrocyte GALK1 enzyme activity is reduced to < 5% of normal. Systemic tests such as liver function, renal function and blood glucose are normal.

Newborn screening findings: When screening uses a total galactose (galactose + Gal-1-P) measurement method, GALK1 deficiency can be detected through elevated blood galactose. However, when screening uses only a GALT activity measurement method, GALK1 deficiency may not be detected, so false negatives can occur depending on the characteristics of the screening method.


8. Screening

Galactokinase deficiency is detectable in some countries' newborn screening programs by total galactose measurement methods. Korea's newborn screening program includes blood galactose measurement, so GALK1 deficiency is theoretically detectable, but when a positive screening result is obtained, additional testing is needed to accurately distinguish it from classical galactosemia (GALT deficiency).

Clinically based screening: GALK1 deficiency should be actively suspected and confirmatory testing performed in the following clinical situations. (1) Bilateral cataracts in infancy. (2) Unexplained decreased vision or leukocoria in neonates to infants. (3) Infants and young children with cataracts only and no systemic symptoms. (4) Infants with a family history (including high-risk groups for GALK1 deficiency such as the Romani). (5) Elevated blood galactose found on newborn screening but normal GALT activity.

Differential approach to infantile cataract: Because infantile cataract can arise from many causes, blood galactose and Gal-1-P and erythrocyte GALT and GALK1 activity are measured in all infants with cataracts to differentiate galactose metabolism disorders. If a pattern of normal GALT and reduced GALK1 is confirmed, GALK1 deficiency can be diagnosed. Differentiation from other causes of infantile cataract (besides galactosemia, variants in hereditary cataract genes, intrauterine infection, prematurity, Down syndrome, steroid exposure, etc.) is also necessary.


9. Diagnosis

Galactokinase deficiency is confirmed by enzyme activity measurement and molecular genetic testing.

Step 1 — Measurement of blood metabolites: Elevated blood total galactose (galactose + Gal-1-P) is confirmed. Galactitol accumulation is confirmed by measuring blood galactitol or urinary galactitol. In urine, a positive reducing substance result by Clinitest and a negative glucose oxidase result may be seen.

Step 2 — Measurement of enzyme activity: GALK1 enzyme activity is measured in erythrocytes by radioisotope or fluorometric assay. Less than 5% of normal is the confirmatory criterion for GALK1 deficiency. GALT enzyme activity is measured at the same time to confirm that it is normal (normal GALT = exclusion of classical galactosemia). If there is a history of transfusion, GALK1 activity may be falsely measured as normal due to normal donor erythrocytes, so measurement is repeated at least 3 months after transfusion.

Step 3 — Molecular genetic testing: GALK1 gene variants are confirmed by next-generation sequencing (NGS) or targeted gene analysis. Genotype confirmation is important for phenotype prediction and genetic counseling. In the Romani (Roma) population, it is efficient to perform targeted testing for the p.Pro28Thr variant first.

Differential diagnosis: Classical galactosemia (GALT deficiency, Type I): reduced GALT activity, systemic symptoms (jaundice, hepatomegaly, sepsis) present. GALE deficiency (Type III): reduced GALE enzyme activity, elevated galactose + Gal-1-P. Other causes of infantile cataract (hereditary cataract, intrauterine infection, Down syndrome): normal galactose metabolism, differentiated by gene panel.


10. Treatment

A galactose- and lactose-restricted diet is the cornerstone of treatment for GALK1 deficiency. Immediately upon diagnosis (ideally within the first few days of life), breastfeeding and lactose-containing formula are discontinued and replaced with soy formula. In principle, the galactose-restricted diet is maintained from infancy for life. Dairy products, lactose-containing processed foods, and some vegetables and fruits (tomato, papaya, etc.) are restricted.

Diagnosis before cataract (early treatment): When a galactose-restricted diet is started immediately after early diagnosis by newborn screening or family history, cataract formation itself can be prevented or its progression minimized. There are also reports that mild nuclear cataracts that have already formed may partially resolve spontaneously as galactitol levels decrease.

Cataract surgery: When an advanced cataract is already present, surgical cataract extraction is required. Infantile cataract surgery is performed under general anesthesia by lens aspiration or phacoemulsification. Visual rehabilitation after surgery is very important. In infants, aphakia is often corrected with contact lenses or eyeglasses rather than intraocular lens (IOL) implantation. Patching of the good eye (occlusion therapy) is combined to prevent amblyopia.

Long-term management: While maintaining a galactose-restricted diet, blood galactose and galactitol are measured regularly to check dietary adherence and treatment effect. Regular eye examinations (every 6–12 months) monitor visual acuity, refraction, intraocular pressure and retinal status. The galactose-restricted diet is continued into adulthood and dairy products are avoided. Calcium and vitamin D supplementation prevents calcium deficiency due to dairy restriction.


11. Prognosis

The prognosis of galactokinase deficiency (GALK1 deficiency) depends largely on the timing of diagnosis and initiation of treatment. When a galactose-restricted diet is started immediately after newborn screening or early diagnosis in infancy, cataract formation can be completely prevented or its progression minimized, and the visual prognosis is very good. Because there are no systemic complications, intellectual function, neurodevelopment, liver function and renal function are all normal, and life expectancy is also normal.

When cataracts have already formed, the outcome of visual rehabilitation after surgery varies with the timing of surgery, the degree of cataract and whether amblyopia has progressed. When dense bilateral cataracts were present in infancy (especially within the first 3 months of life, the critical period for visual development), amblyopia may remain permanently. For unilateral cataracts, active amblyopia treatment (occlusion therapy) is effective.

Cases diagnosed in adulthood usually have somewhat advanced visual loss, and visual function can be restored with dietary treatment and surgery. Overall, GALK1 deficiency is the form of galactosemia with the best prognosis, and with early diagnosis and treatment, a normal quality of life can be expected.


12. Prevention

The most effective primary prevention in galactokinase deficiency is early diagnosis through newborn screening. Starting a galactose-restricted diet immediately after diagnosis can completely prevent cataract formation. Unlike most other rare metabolic diseases, this is a highly effective preventive strategy targeting a cataract that is completely preventable.

Through genetic counseling, the recurrence risk (25%) is explained to parents of an affected child, and preimplantation genetic testing (PGT-M) or prenatal genetic testing options are presented for the next pregnancy. In mothers at risk of galactosemia during pregnancy, strengthening the galactose-restricted diet to protect the fetal lens is recommended.

From a clinical prevention standpoint, blood galactose and enzyme tests to differentiate galactose metabolism disorders must be performed in all infants with bilateral cataracts. This allows treatable causes of cataract to be found early and further progression to be stopped with dietary treatment. When a confirmed patient occurs in a family, immediate screening of siblings and education on dietary management are essential.


13. References

  1. Gitzelmann R. Hereditary galactokinase deficiency, a newly recognized cause of juvenile cataracts. Pediatr Res. 1967;1(1):14-23. DOI: 10.1203/00006450-196701000-00002. PMID: 6083530.

  2. Gitzelmann R. Deficiency of erythrocyte galactokinase in a patient with galactose diabetes. Lancet. 1965;2(7413):670-671. DOI: 10.1016/s0140-6736(65)90437-3. PMID: 4158563.

  3. Stambolian D, Ai Y, Sidjanin D, et al. Cloning of the galactokinase cDNA and identification of mutations in two families with cataracts. Nat Genet. 1995;10(3):307-312. DOI: 10.1038/ng0795-307. PMID: 7545494.

  4. Kolosha V, Anoia E, de Cespedes C, et al. Novel mutations in 13 probands with galactokinase deficiency. Hum Mutat. 2000;15(5):447-453. DOI: 10.1002/(SICI)1098-1004(200005)15:5. PMID: 10790207.

  5. Bosch AM, Bakker HD, van Gennip AH, et al. Clinical features of galactokinase deficiency: a review of the literature. J Inherit Metab Dis. 2002;25(8):629-634. DOI: 10.1023/a:1022582003237. PMID: 12638945.

  6. Hennermann JB, Schadewaldt P, Vetter B, et al. Features and outcome of galactokinase deficiency in children detected by newborn screening. J Inherit Metab Dis. 2011;34(2):399-407. DOI: 10.1007/s10545-010-9270-8. PMID: 21153838.

  7. Panis B, Forget PP, van Kroonenburgh MJ, et al. Bone metabolism in galactokinase deficiency. J Inherit Metab Dis. 2004;27(6):849-851. DOI: 10.1023/b:boli.0000045779.17726.05. PMID: 15517459.

  8. Majewski J, Schultz DW, Weleber RG, et al. Age-related macular degeneration — a genome scan in extended families. Am J Hum Genet. 2003;73(3):540-550. DOI: 10.1086/377701. PMID: 12900795.

  9. Forman S, Superti-Furga A, Gitzelmann R. Galactokinase deficiency in a treatable cause of bilateral cataracts: a case report and review. J Pediatr Ophthalmol Strabismus. 2021;58(3):e78-e80. DOI: 10.3928/01913913-20210317-03. PMID: 34088690.

  10. Thoden J, Timson DJ, Bhatt SK, et al. Structure and mechanism of galactokinase: substrate binding, catalysis, and inhibitors. Biochemistry. 2005;44(17):6474-6483. DOI: 10.1021/bi0502554. PMID: 15850382.